Weltruza Kit
Product Images NDC 51759-348

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Weltruza (NDC 51759-348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 1)

An instructional diagram illustrating supplies used in each step for preparing and administering WELTRUZA (olanzapine) subcutaneous kit. The steps are labeled as Stage A Warm, Stage B Reconstitute, Stage C Withdraw, and Stage D Injection, showing respective items: prefilled diluent syringe and warming pack; vial of WELTRUZA and vial adapter; administration syringe; and administration needle.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 2)

An instructional illustration showing hands pressing on a small central area of a rectangular packet, producing a "CLICK" sound, likely demonstrating the activation or preparation of the WELTRUZA subcutaneous kit.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 3)

An illustration showing a KIT containing a syringe labeled WELTRUZA (olanzapine) with white fastening strips indicated to secure the contents inside the kit.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 4)

An instructional illustration showing a prefilled syringe inside a clear pouch next to a stopwatch icon with the text '15 MIN,' likely indicating a 15-minute wait or observation period related to the subcutaneous WELTRUZA (olanzapine) kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 5)

An instructional illustration showing a hand holding a vial by the cap with arrows indicating an up and down tapping motion on the vial bottom. The word "TAP" is displayed to emphasize the tapping action, suggesting a step in preparing medication, consistent with the WELTRUZA olanzapine subcutaneous injection kit.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 6)

An illustration showing a vial containing liquid medication. The vial is shown upright, with shading indicating the liquid level inside. A checkmark symbol is positioned near the vial, suggesting verification or correctness.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 7)

An instructional diagram showing two steps involving a small vial. The first step illustrates removing a cap from the vial, and the second step demonstrates peeling away a seal or covering from the vial's top using fingers.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 8)

An instructional illustration of a subcutaneous injection device for WELTRUZA (olanzapine) showing a step where the device is pressed downward until a "click" is heard, indicating activation or readiness for use.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 9)

An instructional illustration depicting the preparation steps for a WELTRUZA subcutaneous injection kit. The left side shows inserting and twisting a component into a vial, while the right side shows drawing liquid into the syringe, indicated by downward arrows and a twisting motion symbol.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 10)

An instructional diagram showing a step in the preparation or assembly of a subcutaneous injection kit. The image depicts a vial with liquid at the bottom and an upward arrow indicating the movement of a component, possibly a cap or connector, from above into the vial. This illustration is likely part of the WELTRUZA kit usage instructions from Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 11)

An instructional illustration showing a hand tapping a WELTRUZA (olanzapine) subcutaneous injection kit vial with arrows indicating an up-and-down motion. A clock icon suggests performing this action for approximately 2 minutes.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 12)

Instructional illustration showing a hand holding a WELTRUZA kit and shaking it back and forth for approximately 30 seconds prior to use. The image emphasizes the action of shaking the subcutaneous injection device as part of the preparation process.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 13)

Illustration showing two circular icons each containing a vial with a cap. The left vial is filled with a uniform gray liquid and marked with a check mark, indicating correct or acceptable condition. The right vial contains a liquid with irregular shapes inside and is marked with an X, indicating incorrect or unacceptable condition.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 14)

An instructional illustration showing a syringe being inserted into a vial for preparing a subcutaneous injection dose. The image includes an arrow indicating downward insertion and a rotational arrow suggesting twisting or mixing.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 15)

An instructional illustration showing hands holding a syringe labeled with withdrawal volume markings. The image directs users to remove air bubbles by moving the plunger back and forth, with arrows indicating the plunger movement. This is related to preparing an injectable dose for administration.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 16)

An instructional illustration showing a syringe and a needle or attachment for subcutaneous administration. The image indicates the step to attach the needle to the syringe with an arrow and the word 'Attach.' This diagram likely supports the use of WELTRUZA (olanzapine) subcutaneous kit by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 17)

An anatomical illustration showing the front view of a human torso with a shaded abdominal area. A dashed line and label indicate the 'Abdomen' as the area of interest, likely demonstrating the injection site for subcutaneous administration.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 18)

An instructional illustration showing hands preparing a subcutaneous injection syringe. One hand holds the syringe labeled 'olanzapine' while the other hand removes a cap or cover, indicated by an arrow pointing away from the syringe.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 19)

An instructional diagram for WELTRUZA (olanzapine) subcutaneous injection kit showing two steps: injecting the liquid at a 45-degree angle into the skin, then waiting 2-3 seconds before removing the syringe from the skin.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 20)

Chemical structure diagram of olanzapine, the active ingredient in WELTRUZA. The diagram shows the molecular framework with nitrogen, sulfur, and carbon atoms, including methyl groups attached to the nitrogen and sulfur-containing rings.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 21)

A line graph showing PANSS total score change from baseline over an 8-week analysis period. The x-axis represents weeks from baseline to week 8, while the y-axis shows the PANSS score change. Four groups are shown: Placebo, WELTRUZA 318 mg, WELTRUZA 425 mg, and WELTRUZA 531 mg. Error bars indicate variability at each time point. The graph includes a table of patient numbers per group over time below the x-axis.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 22)

WELTRUZA (olanzapine) 318 mg vial, extended-release injectable suspension, subcutaneous kit by Teva Pharmaceuticals USA, Inc. The label includes kit contents such as a single-dose vial, diluent syringe, warming pack, vial adapter, administration syringe, and 21-gauge administration needle. The product is for administration by a healthcare professional and must be reconstituted before use.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 23)

WELTRUZA (olanzapine) 425 mg/vial extended-release injectable suspension kit for subcutaneous use by healthcare professionals. The label includes kit contents such as a single-dose vial, prefilled syringe diluent, warming pack, vial adapter, administration syringe, and 21-gauge needle. Manufactured by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image (Weltruza Olanzapine Er Inj Susp N219007 24)

WELTRUZA (olanzapine) 531 mg/vial extended-release injectable suspension kit for subcutaneous use only. The label includes kit contents: one single-dose vial of 531 mg olanzapine, one 1.5 mL prefilled syringe of diluent for reconstitution, one warming pack, one vial adapter, one administration syringe, and one 21-gauge, 5/8-inch administration needle. Dispensed by Teva Pharmaceuticals USA, Inc. Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.